Vildagliptin in clinical practice: A review of literature

Moulinath Banerjee; Naveed Younis; Handrean Soran

doi:10.1517/14656560903302265

Vildagliptin in clinical practice: A review of literature

Moulinath Banerjee, Naveed Younis, Handrean Soran^*

^*Corresponding author for this work

Medical School

Manchester University NHS Foundation Trust

Research output: Contribution to journal › Review article › peer-review

33 Citations (Scopus)

Abstract

Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.

Original language	English
Pages (from-to)	2745-2757
Number of pages	13
Journal	Expert Opinion on Pharmacotherapy
Volume	10
Issue number	16
DOIs	https://doi.org/10.1517/14656560903302265
Publication status	Published - 30 Oct 2009

Keywords

DPP-IV inhibitors
Oral hypoglycaemic
Type 2 diabetes
Vildagliptin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/14656560903302265

Cite this

@article{00ebca30c7154e59a047e7f15355f063,

title = "Vildagliptin in clinical practice: A review of literature",

abstract = "Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.",

keywords = "DPP-IV inhibitors, Oral hypoglycaemic, Type 2 diabetes, Vildagliptin",

author = "Moulinath Banerjee and Naveed Younis and Handrean Soran",

year = "2009",

month = oct,

day = "30",

doi = "10.1517/14656560903302265",

language = "English",

volume = "10",

pages = "2745--2757",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor and Francis Ltd.",

number = "16",

}

TY - JOUR

T1 - Vildagliptin in clinical practice

T2 - A review of literature

AU - Banerjee, Moulinath

AU - Younis, Naveed

AU - Soran, Handrean

PY - 2009/10/30

Y1 - 2009/10/30

N2 - Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.

AB - Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.

KW - DPP-IV inhibitors

KW - Oral hypoglycaemic

KW - Type 2 diabetes

KW - Vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=72949090565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949090565&partnerID=8YFLogxK

U2 - 10.1517/14656560903302265

DO - 10.1517/14656560903302265

M3 - Review article

C2 - 19874253

AN - SCOPUS:72949090565

SN - 1465-6566

VL - 10

SP - 2745

EP - 2757

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 16

ER -

Vildagliptin in clinical practice: A review of literature

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this